top of page
ExoProTherMedical Logo
Lana Volokh CEO ExoProTherMedical
Lana Volokh
CEO

ExoProTher Medical is developing a first-in class oncology therapeutics delivery platform targeting cancers with mutation in gene TP53- the most frequently observed genetic alteration in human.  It uses exosomes, natural nanoparticles produced by most living cells, to deliver healthy p53 and restore the body’s natural tumor suppression function with minimal adverse side effects.

stripBIG-01.jpg

PORTFOLIO

Product
icon-08.png

DEVICES

icon-09.png
icon-07.png

PHARMA & BIOTECH

icon-10.png
icon-06.png

PHARMA & BIOTECH

icon-11.png
bottom of page